Navin Fluorine International Ltd Q2 FY2026 Concall Summary

Key Takeaways

• H1 revenue +42%, EBITDA more than doubled: All three verticals delivered strong growth, with CDMO nearly doubling YoY and the new fluoro specialty plant contributing meaningfully.
• Two new capex approvals signal confidence: INR236.5 crores for additional R32 capacity and INR75 crores for MPP debottlenecking, both targeting Q3 FY27 commissioning, funded through internal accruals.
• CDMO lumpiness declared "a thing of the past": Consecutive strong quarters and a repeat order locked for CY26 support the claim, though the aspirational $100 mn target remains scale-dependent rather than a hard commitment.
• R32 supply story keeps tightening: Global cuts under the Kigali Amendment, rising RAC demand, and India's post-2026 capacity freeze create a structural tailwind management is positioning to capture.
• What to watch next quarter: Commercial supply start from the Fermion dedicated plant in January, progress on the three new CDMO customer audits, and any concrete update on the Honeywell relationship expansion.

R32: Capacity, Pricing & the Kigali Tailwind

• New capacity approved: Board sanctioned INR236.5 crores for additional HFC capacity equivalent to 15,000 MTPA of R32, consolidating Navin's position in refrigerant gases with commissioning targeted for Q3 FY27 and peak revenue potential of INR600–825 crores per annum.
• Structural supply squeeze: Global R32 demand ex-China is growing at ~5% CAGR while supply faces mandatory step-downs: a 10% cut in China by 2029, ongoing Western cuts, and India's own cuts starting 2032. After 2026, no new capacity can be added in India.
• Pricing firmness expected to hold: Management sees demand tailwinds far outweighing supply concerns and believes additional supply can only come from India, supporting a firm pricing environment for the foreseeable future.
• Placement strategy protects margin: The company takes a balanced approach between committed and open positions, placing product to avoid oversupply while ensuring margins are not compromised. Management declined to disclose the contractual vs. spot split.
• Utilization visibility: Navin expects to offload its entire quota allowed to manufacture, with strong visibility based on arrangements already in place, though the planned utilization rate was not quantified.

Ganatra: "Everything that we see, it only means that the supply is going to get more and more constrained. I mean, come '29, you're going to see a 10% cut some in China, too, right? And everywhere else in the West, you're seeing the cut coming in. Come 32, you will start to see cuts happening in India, too."

CDMO: The Inflection Narrative

• Revenue nearly doubled: CDMO grew 98% YoY to INR134 crores in Q2, with the European CDMO partner relationship strengthening and a new late-stage molecule delivered to another EU major during the quarter.
• Lumpiness called over: Management stated flatly that lumpiness is "going to be a thing of the past," pointing to two consecutive strong quarters and a repeat order already secured for CY26. One large supply was completed this quarter.
• Fermion dedicated plant ready: Commissioning occurred one month prior; validation batches are underway for each step, with commercial supply to start from January 2026.
• Pipeline building beyond the anchor partner: Three large pharma companies are currently auditing the CDMO plant, and the company continues to collaborate with global agro and advanced material partners on new molecules across CRO and scale-up campaigns.
• The aspirational $100 mn target: Management reiterated the figure as aspirational, emphasizing that the absolute number matters less than the scale achieved when approaching it, with visibility described as "very, very strong."
• Second-half trajectory: The order book is strong and management is striving for H2 to outperform H1, which already delivered ~50% YoY growth.

Ganatra: "The lumpiness, I think, and I'm going to say this, is going to be a thing of past for us, okay? Because you can see that in the consecutive 2 quarters that we've done and we don't think you will see the lumpiness."

Specialty & HPP: Volume-Led Margin Expansion

• HPP revenue crossed INR400 crores: Up 38% YoY, driven by higher realizations and volumes across both domestic and international markets, with Dahej and Surat plants running at optimal capacity.
• Specialty revenue grew 39% YoY: The fluoro specialty plant commissioned in December 2024 began contributing meaningfully this quarter and is now operating at optimum capacity, with strong order booking through to calendar year 2026.
• Operating leverage delivered: EBITDA margin expanded from 20.7% to 32.5%, with roughly three-quarters of the EBITDA growth coming from volume, validating the operating leverage thesis. Some forex tailwind was largely absorbed by sub-sourcing costs.
• Efficiency focus is twofold: Management is driving variable costs down through better utility usage and reduced effluent cost, while keeping fixed costs fixed.
• Margin trajectory: More upside than downside to the 25% EBITDA margin level, with midterm aspirations to move closer to 30%.

Ganatra: "So like I said before, there is more upside to that 25% than downside. So we are certainly working to be closer to 30% in the midterm, but that's what we are working to."

New Projects & Capex Pipeline

• AHF project nearing completion: Mechanical trials are underway, with commissioning expected by Q3 FY26.
• Chemours Opteon project on track: The two-phase immersion cooling fluid manufacturing project is progressing well, targeting completion by Q1 FY27.
• MPP debottlenecking sanctioned: INR75 crores approved to deepen partnerships with global innovators, targeting Q3 FY27 commissioning with peak revenue potential of INR140–160 crores per annum. A firm order for CY26 has already been received from a global innovator for a key intermediate supporting their novel AI.
• Nectar Life Sciences ramp-up: The second product has commenced, with the anchor customer holding firm offtake orders. Full utilization is expected by March 2027.
• Ag chem intermediate win: A novel herbicide intermediate with significant growth aspirations for the innovator has been secured; Navin is participating in that growth trajectory.
• Advanced materials vertical taking shape: Management continues working toward carving out a separate advanced materials vertical, with high-purity electronic grade HF development work progressing.
• Value-accretive capex beyond FY27: The newly announced capex is expected to start accelerating growth beyond FY27.

Mafatlal: "It is our strategic priority to play to our strengths in this business, utilizing our available entitlement under Kigali Montreal Protocol, ensuring a balanced play across blends and 32, maximizing value for our shareholders."

Ag Chem Strategy: Disciplined Investment

• Constructive but disciplined: Management remains constructive on the long-term growth scenario in ag chem and will continue investing, but with discipline: extending utilization and sweating assets harder rather than chasing capacity for its own sake.
• Closer innovator relationships yielding results: The strategy of deepening ties with global innovators to capture share of their future R&D pipeline is paying off, with the new MPP debottlenecking project as evidence.
• Novel AI intermediate potential: The INR75 crore MPP debottlenecking plant is for a novel AI intermediate (not an active ingredient), with potential to grow bigger over time.

Ganatra: "We've always maintained that in the ag chem sector, we will be continuing to invest because we again remain very constructive of the long-term growth scenario in that business. But we are going to be very disciplined. We are going to be extending our utilization and sweating the assets more and more, and that's exactly what you see being played out as we speak."

Guidance & Commitments

Key Metrics